StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3074% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Earnings

Fennec Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
–
EPS, Q4 FY2025
-$0.17
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Fennec Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 24, 2026after the close––-$0.17Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025after the close–––Release
Q4 FY2023ended Dec 31, 2023Mar 6, 2024after the close–––Release
Q3 FY2023ended Sep 30, 2023Nov 7, 2023after the close$6.52M–-$0.07Release
Q2 FY2023ended Jun 30, 2023Aug 4, 2023during market hours$3.33M–-$0.21Release
Q4 FY2019ended Dec 31, 2019Feb 14, 2020during market hours–––Filing
Q3 FY2019ended Sep 30, 2019Nov 12, 2019during market hours–––Filing
Q2 FY2019ended Jun 30, 2019Aug 9, 2019during market hours–––Filing
Q1 FY2019ended Mar 31, 2019May 9, 2019after the close–––Filing
Q4 FY2018ended Dec 31, 2018Mar 14, 2019before the open–––Filing
Q2 FY2010ended Jun 30, 2010Aug 16, 2010during market hours–––Filing
Q4 FY2006ended Dec 31, 2006Mar 28, 2007during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Fennec Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Fennec Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Fennec Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. News
  3. News
  4. News
  5. Results
  6. News
  7. News
  8. News
  9. News
  10. News
  11. News
  12. News
  13. News
  14. News
  15. News

See a number that looks wrong?